View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Jul. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	SGMO
Entity Registrant Name	SANGAMO THERAPEUTICS, INC
Entity Central Index Key	0001001233
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		83,610,838

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 69,837	$ 22,061
Marketable securities	180,074	120,474
Interest receivable	256	224
Accounts receivable	3,495	4,972
Prepaid expenses	2,015	1,849
Total current assets	255,677	149,580
Marketable securities, non-current	16,343
Property and equipment, net	8,347	6,557
Goodwill	1,585	1,585
Other assets	1,041	169
Total assets	282,993	157,891
Current liabilities:
Accounts payable and accrued liabilities	9,206	6,261
Accrued compensation and employee benefits	2,909	2,885
Deferred revenues	29,542	4,145
Total current liabilities	41,657	13,291
Deferred revenues, non-current	43,409	4,460
Build-to-suit lease obligation	3,887	3,945
Total liabilities	88,953	21,696
Commitments and contingencies
Stockholders' equity:
Common stock, $0.01 par value; 160,000,000 shares authorized, 83,479,539 and 70,871,902 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	835	709
Additional paid-in capital	663,382	576,377
Accumulated deficit	(470,034)	(440,911)
Accumulated other comprehensive (loss) income	(143)	20
Total stockholders' equity	194,040	136,195
Total liabilities and stockholders' equity	$ 282,993	$ 157,891

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	83,479,539	70,871,902
Common stock, shares outstanding	83,479,539	70,871,902

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Collaboration agreements	$ 7,977	$ 3,592	$ 11,283	$ 7,303
Research grants	276	110	395	341
Total revenues	8,253	3,702	11,678	7,644
Operating expenses:
Research and development	14,984	19,454	27,926	34,720
General and administrative	6,037	11,090	13,312	16,447
Total operating expenses	21,021	30,544	41,238	51,167
Loss from operations	(12,768)	(26,842)	(29,560)	(43,523)
Interest and other income, net	277	243	437	430
Loss before income taxes	(12,491)	(26,599)	(29,123)	(43,093)
Benefit from income taxes		24		24
Net loss	$ (12,491)	$ (26,575)	$ (29,123)	$ (43,069)
Basic and diluted net loss per share	$ (0.17)	$ (0.38)	$ (0.41)	$ (0.61)
Shares used in computing basic and diluted net loss per share	72,527	70,487	71,780	70,430

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (12,491)	$ (26,575)	$ (29,123)	$ (43,069)
Change in unrealized (loss) gain on available-for-sale securities, net of tax	(51)	8	(163)	91
Comprehensive loss	$ (12,542)	$ (26,567)	$ (29,286)	$ (42,978)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating Activities:
Net loss	$ (29,123)	$ (43,069)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	618	493
Amortization of premium on marketable securities	32	133
Stock-based compensation	4,751	10,393
Benefit from income taxes		(24)
Net changes in operating assets and liabilities:
Interest receivable	(32)	8
Accounts receivable	1,477	216
Prepaid expenses and other assets	(1,039)	(510)
Accounts payable and accrued liabilities	2,654	(1,232)
Accrued compensation and employee benefits	24	(546)
Deferred revenues	64,346	(2,399)
Net cash provided by / (used in) operating activities	43,708	(36,537)
Investing Activities:
Purchases of marketable securities	(159,166)	(145,890)
Maturities of marketable securities	83,029	126,087
Purchases of property and equipment	(2,175)	(356)
Net cash used in investing activities	(78,312)	(20,159)
Financing Activities:
Proceeds from public offering of common stock, net of issuance costs	81,562
Taxes paid related to net share settlement of equity awards	(7)	(534)
Proceeds from issuance of common stock	825	703
Net cash provided by financing activities	82,380	169
Net increase / (decrease) in cash and cash equivalents	47,776	(56,527)
Cash and cash equivalents, beginning of period	22,061	69,482
Cash and cash equivalents, end of period	69,837	12,955
Supplemental disclosure of noncash investing activities:
Property and equipment included in accrued liabilities	$ 226	$ 247

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	NOTE 1—BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The condensed consolidated balance sheet data at December 31, 2016 were derived from the audited consolidated financial statements included in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2016, (the “2016 Annual Report”), as filed with the SEC. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December 31, 2016, included in the 2016 Annual Report Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Revenue Recognition Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee’s product sales. For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January 1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using Vendor Specific Objective Evidence (“VSOE”) of selling price or Third Party Evidence (“TPE”) of selling price. If neither exists, the Company uses Estimated Selling Price (“ESP”) for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements, as amended, entered into with (i) Shire International GmbH, formerly Shire AG (“Shire”), in January 2012, (ii) Bioverativ, formerly Biogen Idec Inc. (“Bioverativ”) in January 2014, as amended, and (iii) Pfizer, Inc. (“Pfizer”) in May 2017 were evaluated under these amended accounting standards. Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company’s performance. Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered assuming all other applicable revenue recognition criteria have been met. Deferred revenue represents the portion of research or license payments received which have not been earned. Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. Recent Accounting Standards In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation – Stock Compensation (Topic 718) (“ASU 2016-09”). ASU 2016-09 involves several aspects of the accounting for share-based transactions, including the income tax consequences, classification of awards as either equity or liabilities, how to account for forfeitures, and classification on the statement of cash flows. The amendments in this update are effective for the Company for its fiscal year 2017. As a result of the adoption of ASU 2016-09, the Company recognized current and prior excess tax benefits related to the exercise of options in its income tax provision. As a result of the Company’s historic, current losses and valuation allowance applied to its deferred tax assets, the gross cumulative effect when considering the federal and state tax impact is $7.5 million. The Company has elected to prospectively apply the amendments related to classifying cash flows related to excess tax benefits as an operating activity. During the quarter ended June 30, 2017 excess tax benefits were classified as an operating activity on the consolidated statement of cash flows, along with other income tax cash flows. The Company has made a policy election to account for forfeitures as they occur. This election was adopted using a modified retrospective approach resulting in an immaterial cumulative effect on retained earnings at the beginning of the period. Prior to the adoption, forfeitures were accounted for using an estimated forfeiture rate. In February 2016, the FASB issued ASU No. 2016-02 Leases (“ASU 2016-02”). ASU 2016-02 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The guidance will become effective for the Company beginning in the first quarter of 2019 with early adoption permitted and will be adopted using a modified retrospective approach. The Company is evaluating the impact of the adoption of this standard on its consolidated financial statements, and expects that its operating lease commitments will be subject to the new standard and recognized as a right-of-use assets and operating lease liabilities upon adoption, which will increase the Company’s total assets and total liabilities as compared to amounts prior to adoption. In May 2014, the FASB issued ASU 2014-09 Revenue from Contracts with Customers (“ASU 2014-09”). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i) apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii) apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). The Company elected to apply the modified retrospective application. This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company has performed a preliminary assessment and continues to evaluate the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements and has determined that the collaborations with Pfizer and Bioverativ are within its scope. The Company assessed the various components of these collaborations under ASC 2014-09 including the upfront license payment, milestones, and research and development services. At this time the Company believes there would be no significant impact to its financial position or results of operations upon adoption of ASU 2014-09.

Fair Value Measurement

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurement

NOTE 2—FAIR VALUE MEASUREMENT

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, and available-for sale-securities. The fair values of these assets were determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The fair value measurements of the Company’s cash equivalents and available-for-sale marketable securities are identified at the following levels within the fair value hierarchy (in thousands):

	June 30, 2017
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	61,385	$	61,385	$	—	$	—
Total		61,385		61,385		—		—
Marketable securities:
Commercial paper securities		65,444		—		65,444		—
Corporate debt securities		64,907		—		64,907		—
U.S. government sponsored entity debt securities		66,066		—		66,066		—
Total		196,417		—		196,417		—
Total cash equivalents and marketable securities	$	257,802	$	61,385	$	196,417	$	—

	December 31, 2016
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	18,992	$	18,992	$	—	$	—
Total		18,992		18,992		—		—
Marketable securities:
Commercial paper securities		23,185		—		23,185		—
Corporate debt securities		10,004		—		10,004		—
U.S. government sponsored entity debt securities		87,285		—		87,285		—
Total		120,474		—		120,474		—
Total cash equivalents and marketable securities	$	139,466	$	18,992	$	120,474	$	—

The Company generally classifies its marketable securities as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

6 Months Ended

Jun. 30, 2017

Investments Debt And Equity Securities [Abstract]

Marketable Securities

NOTE 3—MARKETABLE SECURITIES

The Company classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of substantially identical assets. Unrealized holding gains and losses are included in accumulated other comprehensive income (loss). Investments that have maturities beyond one year as of the end of the reporting period are classified as non-current.

The Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, which is determined using the specific identification method

The table below summarizes the Company’s investments (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		(Losses)			Fair Value
June 30, 2017
Cash equivalents:
Money market funds	$	61,385	$	—	$	—		$	61,385
Total		61,385		—		—			61,385
Available-for-sale securities:
Commercial paper securities		65,465		—		(21	)		65,444
Corporate debt securities		64,943		—		(36	)		64,907
U.S. government sponsored entity debt securities		66,122		—		(56	)		66,066
Total		196,530		—		(113	)		196,417
Total cash equivalents and available-for-sale securities	$	257,915	$	—	$	(113	)	$	257,802
December 31, 2016
Cash equivalents:
Money market funds	$	18,992	$	—	$	—		$	18,992
Total		18,992		—		—			18,992
Available-for-sale securities:
Commercial paper securities		23,112		73		—			23,185
Corporate debt securities		10,005		—		(1	)		10,004
U.S. government sponsored entity debt securities		87,307		3		(25	)		87,285
Total		120,424		76		(26	)		120,474
Total cash equivalents and available-for-sale securities	$	139,416	$	76	$	(26	)	$	139,466

The Company had no material realized losses or other-than-temporary impairments of its investments for the six months ended June 30, 2017 or the twelve months ended December 31, 2016. As of June 30, 2017 and December 31, 2016, all of the Company’s investments had maturity dates within two years. The Company has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value.

Basic and Diluted Net Loss Per Share	6 Months Ended
Basic and Diluted Net Loss Per Share	Jun. 30, 2017
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	NOTE 4—BASIC AND DILUTED NET LOSS PER SHARE Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period. Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of stock options and restricted stock units, which are all anti-dilutive. The total number of shares subject to stock options and restricted stock units outstanding were excluded from consideration in the calculation of diluted net loss per share. Stock options and restricted stock units outstanding for the six months ended June 30, 2017 and 2016 were 9,898,588 and 9,408,253, respectively.

Major Customers, Partnerships and Strategic Alliances

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Major Customers, Partnerships and Strategic Alliances

NOTE 5—MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES

Collaboration Agreements

Collaboration and License Agreement with Pfizer Inc. in Human Therapeutics

On May 10, 2017, Sangamo entered into an Exclusive, Global Collaboration and License Agreement (the “Pfizer Agreement”) with Pfizer, Inc. pursuant to which Sangamo and Pfizer established a collaboration for the research, development and commercialization of SB-525, Sangamo’s gene therapy product candidate for hemophilia A, and closely related products.

Under the Pfizer Agreement, Sangamo will be responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer will be responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. Sangamo and Pfizer may also collaborate in the research and development of additional adeno-associated virus (“AAV”)-based gene therapy products for hemophilia A.

Under the Pfizer Agreement, Sangamo received an upfront fee of $70.0 million from Pfizer. In addition, Sangamo is eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the Pfizer Agreement, is $475.0 million, which includes up to $300.0 million for SB-525 and up to $175.0 million for other products that may be developed under the Pfizer Agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer has agreed to pay Sangamo royalties for each potential licensed product developed under the Pfizer Agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third party intellectual property. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Pfizer Agreement.

Subject to the terms of the Pfizer Agreement, Sangamo granted Pfizer an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by Sangamo for the purpose of developing, manufacturing and commercializing SB-525 and related products. Under the Pfizer Agreement, Pfizer granted Sangamo a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the Pfizer Agreement and controlled by Pfizer to manufacture Sangamo’s products that utilize the AAV delivery system. During a specified period, neither Sangamo nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.

The Company has identified the deliverables within the Pfizer Agreement as a license to the technology and on-going services. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the Pfizer Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a thirty-two month estimated time over which the Company will perform services. The recognition period will be reviewed quarterly and adjusted, as needed, to reflect the Company’s current assumptions regarding the period of performance. As of June 30, 2017, the Company had deferred revenue of $66.2 million related to the Pfizer Agreement. During the three months ended June 30, 2017 the Company recognized revenue of $3.8 million related to the upfront fee.

Collaboration and License Agreement with Bioverativ Inc. in Human Therapeutics

In January 2014 the Company entered into a Global Research, Development and Commercialization Collaboration and License Agreement with Biogen, Inc., and in January 2017 this agreement was assigned by Biogen to its blood disorder spin-off, Bioverativ (the “Bioverativ Agreement”). Pursuant to the Bioverativ Agreement, Sangamo and Bioverativ collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo’s zinc finger DNA-binding protein (“ZFP”) technology for hemoglobinopathies, including beta-thalassemia and sickle cell disease (“SCD”).

Under the Bioverativ Agreement, Sangamo and Bioverativ jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first therapeutic developed under the Bioverativ Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (“IND”) application for a ZFP-based therapeutic intended to treat SCD. For both programs, Bioverativ is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Bioverativ Agreement. At the end of specified research terms for each program or under certain specified circumstances, Bioverativ retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any licensed products to treat beta-thalassemia and SCD developed under the Bioverativ Agreement, and Bioverativ agrees to compensate Sangamo for such co-promotion activities.

Sangamo received an upfront license fee of $20.0 million upon entering into the Bioverativ Agreement. In addition, the Company will also be eligible to receive $115.8 million in payments upon the achievement of specified research, regulatory, clinical development milestones, as well as $160.5 million in payments upon the achievement of specified commercialization and sales milestones. Bioverativ reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo, including Phase 1 contingent payments of $7.5 million for the SCD program and $6.0 million for the beta-thalassemia program. In addition, if products are commercialized under the Bioverativ Agreement, Bioverativ will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Bioverativ Agreement.

In January 2016, the parties agreed on an updated beta-thalassemia development plan and budget using the BCL11A Enhancer target. In November 2016, Sangamo and Bioverativ agreed on an updated beta-thalassemia development plan and budget. As a result of this change, the Company updated the estimated performance period of the upfront license through June 2020, and updated the milestones to be received based on the updated performance period of its deliverables under the Bioverativ Agreement.

All contingent payments under the Bioverativ Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Bioverativ Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i) that can be achieved based in whole or in part on either the Company’s performance or on the occurrence of a specific outcome resulting from the Company’s performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii) that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Bioverativ Agreement, assuming all other applicable revenue recognition criteria have been met.

Subject to the terms of the Bioverativ Agreement, Sangamo has granted Bioverativ an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Bioverativ Agreement. Sangamo has also granted Bioverativ a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, under Sangamo’s interest in certain other intellectual property developed pursuant to the Bioverativ Agreement.

The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Bioverativ apart from the research services to be performed pursuant to the Bioverativ Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a forty-four month estimated research term as of the November 2016 modification date, during which time the Company will perform research services. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company’s current assumptions regarding the timing of its deliverables. As of June 30, 2017, the Company had deferred revenue of $5.5 million related to the Bioverativ Agreement.

Revenues recognized under the agreement with Bioverativ for the three months and six months ended June 30, 2017 and 2016 were as follows (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Revenue related to Bioverativ Collaboration:
Recognition of upfront fee	$	442	$	608	$	884	$	1,216
Research services		3,068		1,894		4,777		3,925
Total	$	3,510	$	2,502	$	5,661	$	5,141

Costs and expenses incurred under the Bioverativ Agreement related to the beta-thalassemia project were $2.9 million and $2.1 million during the three months ended June 30, 2017 and 2016, respectively, and $4.5 million and $4.1 million during the six months ended June 30, 2017 and, 2016, respectively.

Amended Collaboration and License Agreement with Shire International GmbH in Human Therapeutics

In January 2012, the Company entered into a Collaboration and License Agreement with Shire (the “Shire Agreement ”), pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on the Company’s novel ZFP technology. This agreement was amended on September 1, 2015, as described in more detail below.

Under the original Shire Agreement, the Company and Shire agreed to develop potential genome editing products or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets may be used for treating or diagnosing hemophilia A and B. Shire had the right, subject to certain limitations, to designate two additional gene targets, and in June 2012, Shire selected a fifth gene target for the development of a therapeutic for Huntington’s disease. Shire had the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo’s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets.

Under the terms of the Shire Agreement, the Company was responsible for all research activities through the submission of an IND or European Clinical Trial Application (“CTA”), while Shire was responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimbursed Sangamo for agreed upon internal and external program-related research costs. The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement in 2012. In 2014 Sangamo recognized a $1.0 million milestone payment related to the hemophilia program.

On September 1, 2015, the Shire Agreement was amended such that Shire agreed to return to Sangamo the exclusive, world-wide rights to gene targets for the development and commercialization of therapeutics for hemophilia A and B. Shire retained the rights and will continue to develop a therapeutic for Huntington’s disease. Sangamo will provide certain target feasibility services, and upon Shire’s request, certain research activities according to a research plan as agreed upon by both companies. Such research activities performed by Sangamo will be reimbursed by Shire. Shire’s rights with respect to other targets contemplated in the original agreement revert to Sangamo. Under the amended agreement, each company is responsible for expenses associated with its own programs and Shire will reimburse Sangamo for any ongoing services provided by Sangamo for Shire’s programs. Sangamo has granted Shire a right of first negotiation to license Sangamo’s hemophilia A and B products for genome editing purposes developed under the amended Shire Agreement based on Sangamo’s ZFP technology. Under the amended agreement, Shire does not have any milestone payment obligations with respect to the retained programs, but it is required to pay single digit percentage royalties to Sangamo, up to a specified maximum cap, on the commercial sales of therapeutic products from such programs. Under the Shire Agreement as amended, Sangamo has full control over, and full responsibility for the costs of, the hemophilia programs returned to it, subject to certain diligence obligations and Shire’s right of first negotiation to obtain a license to such programs under certain circumstances. The Company is required to pay single digit percentage royalties to Shire, up to a specified maximum cap, on commercial sales of therapeutic products from such returned programs.

The Company has identified the deliverables within the amended arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire amendment. Sangamo continues to be responsible for research activities related to the licensed technology with Shire under the amendment. As a result, the Company will continue to recognize revenue from the upfront payment received upon entering into the original Shire agreement in 2012 on a straight-line basis over the six-year initial research term during which the Company expects to perform research services. As of June 30, 2017, the Company had deferred revenue of $1.2 million related to the Shire Agreement, as amended.

Revenues recognized under the agreement with Shire for the three and six months ended June 30, 2017 and 2016 were as follows (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Revenue related to Shire Collaboration:
Recognition of upfront fee	$	583	$	541	$	1,167	$	1,083
Research services		3		363		110		792
Total	$	586	$	904	$	1,277	$	1,875

Related costs and expenses incurred under the Shire agreement were $0.0 million and $0.3 million during the three months ended June 30, 2017 and 2016, and $0.1 million and $0.7 million during the six months ended June 30, 2017 and 2016, respectively..

Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering

In July 2007, the Company entered into a license agreement (the “Sigma Agreement”) with Sigma-Aldrich Corporation (“Sigma”). Under the Sigma Agreement, Sangamo agreed to provide Sigma with access to Sangamo’s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (DAS). Under the Sigma Agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using Sangamo’s ZFP technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company’s ZFP technology in the research field. Sangamo has transferred its ZFP manufacturing technology to Sigma.

In October 2009, the Company expanded the Sigma Agreement. In addition to the original terms of the Sigma Agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein and other pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the expanded agreement, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. Sangamo has received commercial license fees of $5.0 million based upon a percentage of net sales and sublicensing revenue for commercial products and once such amount was received, the Company receives a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million.

Revenues recognized under the agreement with Sigma for the three and six months ended June 30, 2017 and 2016 were as follows (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Revenue related to Sigma Collaboration:
Royalty revenues	$	19	$	49	$	50	$	61
License fee revenues		—		63		267		70
Total	$	19	$	112	$	317	$	131

Related costs and expenses incurred under the Sigma agreement were $0.0 million during both the three and six months ended June 30, 2017 and 2016, respectively.

Agreement with Dow AgroSciences in Plant Agriculture

In October 2005 the Company entered into an exclusive commercial license agreement with DAS. Under this agreement, Sangamo provides DAS with access to proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP transcription factors (“ZFP TFs”) or ZFP nucleases (“ZFNs”) into humans or animals for diagnostic, therapeutic or prophylactic purposes. The Company’s agreement with DAS provided for an initial three-year research term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company’s ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo’s ZFP technology to third parties for use in plant cells, plants or plant cell cultures and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December 31, 2012.

The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the Agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over eleven years. The Company does not have any ongoing performance obligations with respect to the sublicensing activities to be conducted by DAS. DAS has the right to terminate the agreement at any time; accordingly, the Company’s actual sublicense fees over the term of the agreement could be lower than $25.3 million. In addition, each party may terminate the agreement upon an uncured material breach by the other party. In the event of any termination of the agreement, all rights to use the Company’s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo’s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company’s ZFP technology.

There were no revenues recognized or costs and expenses incurred under this agreement during the three and six months ended June 30, 2017 and 2016, respectively.

Funding from Research Foundations

California Institute for Regenerative Medicine (“CIRM”) - HIV

In May 2014, CIRM agreed to fund a $5.6 million Strategic Partnership Award to fund the clinical studies of a potentially curative therapeutic for HIV/AIDS based on the application of Sangamo’s ZFN genome editing technology in hematopoietic stem and progenitor cells (“HSPCs”). The four-year grant provides matching funds to support evaluation of the Company’s stem cell-based therapeutic in a clinical trial in HIV-infected individuals conducted at City of Hope.

There were no revenues attributable to research and development performed under this Strategic Partnership Award during the three and six months ended either June 30, 2017 or 2016. Related costs and expenses incurred under the CIRM Strategic Partnership Award were $0.1 million and $0.4 million during the three months ended June 30, 2017 and 2016, respectively, and $0.3 million and $0.7 million during the six months ended June 30, 2017 and 2016, respectively.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 6—INCOME TAXES The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo’s history of losses. Accordingly, the Company’s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.

Stock-Based Compensation

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

NOTE 7—STOCK-BASED COMPENSATION

The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016 (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Research and development	$	1,218	$	1,728	$	2,436	$	3,578
General and administrative		746		5,471		2,315		6,815
Total stock-based compensation expense	$	1,964	$	7,199	$	4,751	$	10,393

Included in the above stock-based compensation table for the six months ended June 30, 2017 is $0.8 million related to a modification of options for the former chief financial officer who retired during the three months ended March 31, 2017. For the three months ended June 30, 2016 the Company recognized $4.1 million in stock-based compensation expense and $2.0 million in salary and benefits associated with separation costs for the transition of the Company’s former chief executive officer in June 2016 (the “CEO Transition”).

Build-to-Suit Lease	6 Months Ended
Build-to-Suit Lease	Jun. 30, 2017
Leases Operating [Abstract]
Build-to-Suit Lease	NOTE 8—BUILD-TO-SUIT LEASE In December 2015, the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 41,400 square feet of space, in Richmond, California. Substantial completion of the building was accomplished in December 2016, at which time the lease commenced. The lease agreement expires in December 2021, five years after substantial completion of the building. The Company has two options to extend the lease term for up to a combined additional ten years. The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner. In connection with the Company’s accounting for this transaction, the Company capitalized the costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. As of June 30, 2017, $3.8 million of costs were capitalized in buildings with a corresponding build-to-suit lease obligation recognized related to this lease. Construction has completed on the facility and as such a portion of the monthly lease payment is allocated to land rent and recorded as an operating lease expense and the non-interest portion of the amortized lease payments to the landlord related to the rent of the building is applied to reduce the build-to-suit lease obligation.

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity	NOTE 9— STOCKHOLDERS’ EQUITY On May 26, 2017, the Company entered into an Amended and Restated At-the-Market Offering Program Sales Agreement (the “2017 ATM Agreement”) with an investment bank pursuant to which the Company may issue and sell from time to time after the date of the 2017 ATM Agreement, shares of its common stock having an aggregate offering price of up to $75.0 million through the investment bank acting as the Company’s sales agent. Under the 2017 ATM Agreement, if the Company decides to sell shares, the Company will notify the sales agent, and the sales agent will use its commercially reasonable efforts to sell on the Company’s behalf all of the shares of common stock requested to be sold. Sales of the Company’s common stock, if any, will be made at market prices by any method that is deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The NASDAQ Global Select Market and sales to or through a market maker other than on an exchange. In addition, with the Company’s prior written consent, the sales agent may also sell shares of its common stock in negotiated transactions under the 2017 ATM Agreement. During the three months ended March 31, 2017, the Company issued a total of 871,149 shares of its common stock under the original At-the-Market Offering Program Sales Agreement entered into with the sales agent in December 2016, and received net proceeds of $3.4 million, after deducting offering expenses, including $0.1 million of commission paid to the sales agent. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior to the time the shares were sold. Consequently, the Company may be subject to claims for rescission by purchasers who purchased shares of common stock under the ATM Agreement in March 2017. Under Section 12(a)(1) of the Securities Act, a purchaser of security in a transaction made in violation of Section 5 of the Securities Act may obtain recovery of the consideration paid in connection with its purchase, plus statutory interest, or, if it had already sold the shares, recover damages resulting from its purchase. While the Company believes, it is unlikely that a successful claim will be asserted against the Company by any purchasers who purchased shares of common stock under the ATM Agreement in March 2017, the Company cannot guarantee that no such legal claims will be asserted against the Company by any purchasers. In addition, the Company could become subject to enforcement actions and/or penalties and fines by federal authorities, and the Company is unable to predict the likelihood of any such enforcement actions being brought, or the amount of any such potential penalties or fines. On June 26, 2017, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 11.5 million shares of its common stock at a public offering price of $7.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $78.1 million.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The condensed consolidated balance sheet data at December 31, 2016 were derived from the audited consolidated financial statements included in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2016, (the “2016 Annual Report”), as filed with the SEC. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December 31, 2016, included in the 2016 Annual Report
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee’s product sales. For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January 1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using Vendor Specific Objective Evidence (“VSOE”) of selling price or Third Party Evidence (“TPE”) of selling price. If neither exists, the Company uses Estimated Selling Price (“ESP”) for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements, as amended, entered into with (i) Shire International GmbH, formerly Shire AG (“Shire”), in January 2012, (ii) Bioverativ, formerly Biogen Idec Inc. (“Bioverativ”) in January 2014, as amended, and (iii) Pfizer, Inc. (“Pfizer”) in May 2017 were evaluated under these amended accounting standards. Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company’s performance. Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered assuming all other applicable revenue recognition criteria have been met. Deferred revenue represents the portion of research or license payments received which have not been earned. Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred.
Recent Accounting Standards	Recent Accounting Standards In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation – Stock Compensation (Topic 718) (“ASU 2016-09”). ASU 2016-09 involves several aspects of the accounting for share-based transactions, including the income tax consequences, classification of awards as either equity or liabilities, how to account for forfeitures, and classification on the statement of cash flows. The amendments in this update are effective for the Company for its fiscal year 2017. As a result of the adoption of ASU 2016-09, the Company recognized current and prior excess tax benefits related to the exercise of options in its income tax provision. As a result of the Company’s historic, current losses and valuation allowance applied to its deferred tax assets, the gross cumulative effect when considering the federal and state tax impact is $7.5 million. The Company has elected to prospectively apply the amendments related to classifying cash flows related to excess tax benefits as an operating activity. During the quarter ended June 30, 2017 excess tax benefits were classified as an operating activity on the consolidated statement of cash flows, along with other income tax cash flows. The Company has made a policy election to account for forfeitures as they occur. This election was adopted using a modified retrospective approach resulting in an immaterial cumulative effect on retained earnings at the beginning of the period. Prior to the adoption, forfeitures were accounted for using an estimated forfeiture rate. In February 2016, the FASB issued ASU No. 2016-02 Leases (“ASU 2016-02”). ASU 2016-02 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The guidance will become effective for the Company beginning in the first quarter of 2019 with early adoption permitted and will be adopted using a modified retrospective approach. The Company is evaluating the impact of the adoption of this standard on its consolidated financial statements, and expects that its operating lease commitments will be subject to the new standard and recognized as a right-of-use assets and operating lease liabilities upon adoption, which will increase the Company’s total assets and total liabilities as compared to amounts prior to adoption. In May 2014, the FASB issued ASU 2014-09 Revenue from Contracts with Customers (“ASU 2014-09”). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i) apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii) apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). The Company elected to apply the modified retrospective application. This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company has performed a preliminary assessment and continues to evaluate the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements and has determined that the collaborations with Pfizer and Bioverativ are within its scope. The Company assessed the various components of these collaborations under ASC 2014-09 including the upfront license payment, milestones, and research and development services. At this time the Company believes there would be no significant impact to its financial position or results of operations upon adoption of ASU 2014-09.

Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Summary of Fair Value Measurements of Cash Equivalents, and Available-for-Sale Marketable Securities

The fair value measurements of the Company’s cash equivalents and available-for-sale marketable securities are identified at the following levels within the fair value hierarchy (in thousands):

	June 30, 2017
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	61,385	$	61,385	$	—	$	—
Total		61,385		61,385		—		—
Marketable securities:
Commercial paper securities		65,444		—		65,444		—
Corporate debt securities		64,907		—		64,907		—
U.S. government sponsored entity debt securities		66,066		—		66,066		—
Total		196,417		—		196,417		—
Total cash equivalents and marketable securities	$	257,802	$	61,385	$	196,417	$	—

	December 31, 2016
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	18,992	$	18,992	$	—	$	—
Total		18,992		18,992		—		—
Marketable securities:
Commercial paper securities		23,185		—		23,185		—
Corporate debt securities		10,004		—		10,004		—
U.S. government sponsored entity debt securities		87,285		—		87,285		—
Total		120,474		—		120,474		—
Total cash equivalents and marketable securities	$	139,466	$	18,992	$	120,474	$	—

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2017

Investments Debt And Equity Securities [Abstract]

Schedule of Investments

The table below summarizes the Company’s investments (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		(Losses)			Fair Value
June 30, 2017
Cash equivalents:
Money market funds	$	61,385	$	—	$	—		$	61,385
Total		61,385		—		—			61,385
Available-for-sale securities:
Commercial paper securities		65,465		—		(21	)		65,444
Corporate debt securities		64,943		—		(36	)		64,907
U.S. government sponsored entity debt securities		66,122		—		(56	)		66,066
Total		196,530		—		(113	)		196,417
Total cash equivalents and available-for-sale securities	$	257,915	$	—	$	(113	)	$	257,802
December 31, 2016
Cash equivalents:
Money market funds	$	18,992	$	—	$	—		$	18,992
Total		18,992		—		—			18,992
Available-for-sale securities:
Commercial paper securities		23,112		73		—			23,185
Corporate debt securities		10,005		—		(1	)		10,004
U.S. government sponsored entity debt securities		87,307		3		(25	)		87,285
Total		120,424		76		(26	)		120,474
Total cash equivalents and available-for-sale securities	$	139,416	$	76	$	(26	)	$	139,466

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Major Customers, Partnerships and Strategic Alliances (Tables)

6 Months Ended

Jun. 30, 2017

Bioverativ Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement with Bioverativ for the three months and six months ended June 30, 2017 and 2016 were as follows (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Revenue related to Bioverativ Collaboration:
Recognition of upfront fee	$	442	$	608	$	884	$	1,216
Research services		3,068		1,894		4,777		3,925
Total	$	3,510	$	2,502	$	5,661	$	5,141

Shire AG [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement with Shire for the three and six months ended June 30, 2017 and 2016 were as follows (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Revenue related to Shire Collaboration:
Recognition of upfront fee	$	583	$	541	$	1,167	$	1,083
Research services		3		363		110		792
Total	$	586	$	904	$	1,277	$	1,875

Sigma-Aldrich Corporation [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement with Sigma for the three and six months ended June 30, 2017 and 2016 were as follows (in thousands):

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Revenue related to Sigma Collaboration:
Royalty revenues	$	19	$	49	$	50	$	61
License fee revenues		—		63		267		70
Total	$	19	$	112	$	317	$	131

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expense

	Three months ended				Six months ended
	June 30,				June 30,
	2017		2016		2017		2016
Research and development	$	1,218	$	1,728	$	2,436	$	3,578
General and administrative		746		5,471		2,315		6,815
Total stock-based compensation expense	$	1,964	$	7,199	$	4,751	$	10,393

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	Jun. 30, 2017 USD ($)
ASU No. 2016-09 [Member]
Change In Accounting Estimate [Line Items]
Gross cumulative effect	$ 7.5

Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, and Available-for-Sale Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents and marketable securities	$ 257,802	$ 139,466
Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	61,385	18,992
Fair value on recurring basis [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	61,385	18,992
Total marketable securities	196,417	120,474
Total cash equivalents and marketable securities	257,802	139,466
Fair value on recurring basis [Member] \| Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	61,385	18,992
Fair value on recurring basis [Member] \| Commercial paper securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	65,444	23,185
Fair value on recurring basis [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	61,385	18,992
Total cash equivalents and marketable securities	61,385	18,992
Fair value on recurring basis [Member] \| Level 1 [Member] \| Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	61,385	18,992
Fair value on recurring basis [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	196,417	120,474
Total cash equivalents and marketable securities	196,417	120,474
Fair value on recurring basis [Member] \| Level 2 [Member] \| Commercial paper securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	65,444	23,185
Fair value on recurring basis [Member] \| Corporate debt securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	64,907	10,004
Fair value on recurring basis [Member] \| Corporate debt securities [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	64,907	10,004
Fair value on recurring basis [Member] \| U.S. government sponsored entity debt securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	66,066	87,285
Fair value on recurring basis [Member] \| U.S. government sponsored entity debt securities [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	$ 66,066	$ 87,285

Marketable Securities - Schedule of Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	$ 69,837	$ 22,061	$ 12,955	$ 69,482
Amortized Cost	257,915	139,416
Gross Unrealized Gains		76
Gross Unrealized (Losses)	(113)	(26)
Estimated Fair Value	257,802	139,466
Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	196,530	120,424
Gross Unrealized Gains		76
Gross Unrealized (Losses)	(113)	(26)
Estimated Fair Value	196,417	120,474
Money market funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	61,385	18,992
Total cash equivalents	61,385	18,992
Cash equivalents [Member]
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	61,385	18,992
Total cash equivalents	61,385	18,992
Commercial paper securities [Member] \| Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	65,465	23,112
Gross Unrealized Gains		73
Gross Unrealized (Losses)	(21)
Estimated Fair Value	65,444	23,185
Corporate debt securities [Member] \| Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	64,943	10,005
Gross Unrealized (Losses)	(36)	(1)
Estimated Fair Value	64,907	10,004
U.S. government sponsored entity debt securities [Member] \| Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	66,122	87,307
Gross Unrealized Gains		3
Gross Unrealized (Losses)	(56)	(25)
Estimated Fair Value	$ 66,066	$ 87,285

Marketable Securities - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Investments Debt And Equity Securities [Abstract]
Realized losses	$ 0	$ 0
Investments other-than-temporarily impaired	$ 0	$ 0
Investments maturity period	2 years	2 years

Basic and Diluted Net Loss Per Share - Additional Information (Detail) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Stock options and restricted stock units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Stock options and restricted stock units outstanding	9,898,588	9,408,253

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)		1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	May 10, 2017 USD ($)	Jan. 31, 2014 USD ($) Program	Jun. 30, 2012 Targets	Jan. 31, 2012 USD ($) Targets	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) Product	Jun. 30, 2016 USD ($)	Dec. 31, 2014 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of research programs \| Program		2
Research and development					$ 14,984,000	$ 19,454,000	$ 27,926,000	$ 34,720,000
Pfizer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement	$ 70,000,000
Milestone revenue receivable	475,000,000
Milestone payments received							$ 0
Number of products approved \| Product							0
Royalty revenues							$ 0
Research program to develop laboratory research reagents							32 months
Deferred revenue					66,200,000		$ 66,200,000
Recognition of upfront fee					3,800,000
Bioverativ Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement		$ 20,000,000
Milestone payments received							$ 0
Number of products approved \| Product							0
Royalty revenues							$ 0
Research program to develop laboratory research reagents							44 months
Deferred revenue					5,500,000		$ 5,500,000
Recognition of upfront fee					442,000	608,000	884,000	1,216,000
Potential amount eligible to receive for certain milestones		115,800,000
Potential amount to be funded for achievement of specified commercialized and sales milestones		160,500,000
Bioverativ Inc [Member] \| Sickle cell disease [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable		7,500,000
Bioverativ Inc [Member] \| Beta-thalassemia Project [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable		$ 6,000,000
Research and development					2,900,000	2,100,000	$ 4,500,000	4,100,000
Shire AG [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement				$ 13,000,000
Research program to develop laboratory research reagents							6 years
Deferred revenue					1,200,000		$ 1,200,000
Recognition of upfront fee					583,000	541,000	1,167,000	1,083,000
Research and development					$ 0	$ 300,000	$ 100,000	$ 700,000
Aggregate number of gene targets \| Targets				7
Number of initial gene targets \| Targets				4
Number of gene targets \| Targets			5
Number of additional gene targets \| Targets			2
Recognition of milestone									$ 1,000,000
Maximum [Member] \| SB-525 [Member] \| Pfizer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable	300,000,000
Maximum [Member] \| Other Products [Member] \| Pfizer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable	$ 175,000,000

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Bioverativ Inc [Member]
Revenues:
Recognition of upfront fee	$ 442,000	$ 608,000	$ 884,000	$ 1,216,000
Royalty revenues			0
Research services	3,068,000	1,894,000	4,777,000	3,925,000
Total	3,510,000	2,502,000	5,661,000	5,141,000
Shire AG [Member]
Revenues:
Recognition of upfront fee	583,000	541,000	1,167,000	1,083,000
Research services	3,000	363,000	110,000	792,000
Total	586,000	904,000	1,277,000	1,875,000
Sigma-Aldrich Corporation [Member]
Revenues:
Royalty revenues	19,000	49,000	50,000	61,000
License fee revenues		63,000	267,000	70,000
Total	$ 19,000	$ 112,000	$ 317,000	$ 131,000

Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Oct. 31, 2009	Jul. 31, 2007	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development			$ 14,984	$ 19,454	$ 27,926	$ 34,720
Sigma-Aldrich Corporation [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research program to develop laboratory research reagents		3 years
Upfront license fee	$ 20,000
Public offering, common stock shares issued	636,133
Reduced royalty rate	10.50%
Funding available under the amended agreement	$ 25,000
Sigma-Aldrich Corporation [Member] \| Upfront license fee [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront license fee	15,100
Common stock issued under license agreement	$ 4,900
Sigma-Aldrich Corporation [Member] \| License agreement terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement					5,000
Research and development			$ 0	$ 0	$ 0	$ 0

Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail) - Dow Agro Sciences [Member] - License agreement terms [Member] - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Oct. 31, 2005	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research program to develop laboratory research reagents	3 years
One-time license fee earned on exercise of option	$ 6,000,000
Royalty revenues	$ 2,300,000
Percentage of royalties to be received from sublicensing	25.00%
Previously agreed research, development and commercialization milestone payments, and royalties on sales of products	$ 4,000,000
Fee due	$ 25,300,000
Minimum license annual fees specific reckoning period	11 years
Revenue attributable to research and development		$ 0	$ 0	$ 0	$ 0
Collaboration agreement costs and expenses		$ 0	$ 0	$ 0	$ 0
Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Annual fees	$ 250,000
Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Annual fees	$ 3,000,000

Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2014	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research grants		$ 276,000	$ 110,000	$ 395,000	$ 341,000
California Institute for Regenerative Medicine [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Funds due under the agreement	$ 5,600,000
Agreement to receive	4 years
Research grants		0	0	0	0
Collaboration agreement related costs and expenses		$ 100,000	$ 400,000	$ 300,000	$ 700,000

Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,964	$ 7,199	$ 4,751	$ 10,393
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,218	1,728	2,436	3,578
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 746	$ 5,471	$ 2,315	$ 6,815

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,964	$ 7,199	$ 4,751	$ 10,393
Former Chief Financial Officer [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense			$ 800
Former Chief Executive Officer [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense		4,100
Salary and benefits associated with separation costs		$ 2,000

Build-to-Suit Lease - Additional Information (Detail) $ in Millions	1 Months Ended	6 Months Ended
	Dec. 31, 2015 ft² Option	Jun. 30, 2017 USD ($)
Operating Leased Assets [Line Items]
Property leased \| ft²	41,400
Lease expiration date		Dec. 31, 2016
Operating lease expiration period	5 years
Number of lease term extension options \| Option	2
Costs capitalized \| $		$ 3.8
Maximum [Member]
Operating Leased Assets [Line Items]
Lease agreement, extendable lease term	10 years

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	6 Months Ended
	Jun. 26, 2017	Mar. 31, 2017	Jun. 30, 2017	May 26, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Net proceeds from issuance of common stock, after deducting offering expenses			$ 81,562
Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Net proceeds from issuance of common stock, after deducting offering expenses	$ 78,100
Total shares issued	11,500,000
Public offering price of common stock issued	$ 7.25
ATM Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issuable and sellable under offering agreement				$ 75,000
ATM Agreement [Member] \| Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Net proceeds from issuance of common stock, after deducting offering expenses		$ 3,400
Total shares issued		871,149
Commission paid to sales agent		$ 100